Detalhe da pesquisa
1.
The contribution of itch and skin severity improvements to the Dermatology Life Quality Index in patients with atopic dermatitis in baricitinib phase III trials.
Br J Dermatol
; 186(6): 1047-1049, 2022 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-35041213
2.
Baricitinib in patients with moderate-to-severe atopic dermatitis: Results from a randomized monotherapy phase 3 trial in the United States and Canada (BREEZE-AD5).
J Am Acad Dermatol
; 85(1): 62-70, 2021 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-33600915
3.
Comparison of real-world treatment patterns among patients with psoriasis prescribed ixekizumab or secukinumab.
J Am Acad Dermatol
; 82(4): 927-935, 2020 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-31712178
4.
Ixekizumab treatment and the impact on SF-36: results from three pivotal phase III randomised controlled trials in patients with moderate-to-severe plaque psoriasis.
Qual Life Res
; 29(2): 369-380, 2020 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-31655974
5.
Nail Psoriasis Does Not Affect Skin Response to Ixekizumab in Patients With Moderate-To-Severe Psoriasis.
J Drugs Dermatol
; 19(8): 741-746, 2020 Aug 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-32845588
6.
Ixekizumab treatment shows a neutral impact on cardiovascular parameters in patients with moderate-to-severe plaque psoriasis: Results from UNCOVER-1, UNCOVER-2, and UNCOVER-3.
J Am Acad Dermatol
; 79(1): 104-109.e8, 2018 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-29548945
7.
Maintenance of skin clearance with ixekizumab treatment of psoriasis: Three-year results from the UNCOVER-3 study.
J Am Acad Dermatol
; 79(5): 824-830.e2, 2018 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-29803904
8.
Real-world health outcomes in adults with moderate-to-severe psoriasis in the United States: a population study using electronic health records to examine patient-perceived treatment effectiveness, medication use, and healthcare resource utilization.
BMC Dermatol
; 18(1): 4, 2018 06 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-29954363
9.
Cost Per Additional Responder Associated With Ixekizumab and Etanercept in the Treatment of Moderate-to-Severe Psoriasis.
J Drugs Dermatol
; 16(12): 1246-1252, 2017 12 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-29240860
10.
Impact of ixekizumab on psoriasis itch severity and other psoriasis symptoms: Results from 3 phase III psoriasis clinical trials.
J Am Acad Dermatol
; 75(6): 1156-1161, 2016 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-27692498
11.
Ixekizumab Is Effective in Subjects With Moderate to Severe Plaque Psoriasis With Significant Nail Involvement: Results From UNCOVER 3.
J Drugs Dermatol
; 15(8): 958-61, 2016 Aug 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-27537996
12.
Inadequate response and treatment patterns in adults diagnosed with atopic dermatitis and treated with topical therapy.
J Dermatolog Treat
; 33(5): 2510-2517, 2022 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-34612129
13.
The current treatment landscape in adult atopic dermatitis in the United States: results from a cross-sectional real-world study.
J Dermatolog Treat
; 33(3): 1707-1717, 2022 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-33752555
14.
US health care utilization and costs in adult patients with atopic dermatitis by disease severity.
J Manag Care Spec Pharm
; 28(1): 69-77, 2022 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-34949118
15.
Assessment of the benefit of achieving complete versus almost complete skin clearance in psoriasis: a patient's perspective.
J Dermatolog Treat
; 33(2): 733-739, 2022 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-32432957
16.
Disease response and patient-reported outcomes among initiators of ixekizumab.
J Dermatolog Treat
; 33(3): 1538-1546, 2022 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-33267635
17.
The direct and indirect costs of adult atopic dermatitis.
J Manag Care Spec Pharm
; 27(10): 1416-1425, 2021 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-34595952
18.
Psoriasis Severity Assessment Combining Physician and Patient Reported Outcomes: The Optimal Psoriasis Assessment Tool.
Dermatol Ther (Heidelb)
; 11(4): 1249-1263, 2021 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-34047947
19.
Ixekizumab treatment patterns and healthcare utilization and costs for patients with psoriasis.
J Dermatolog Treat
; 32(1): 56-63, 2021 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-31696745
20.
Understanding characteristics of patients newly initiating ixekizumab: findings from the Corrona Psoriasis Registry.
J Comp Eff Res
; 10(2): 157-167, 2021 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-33355477